Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Current Assets (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Current Assets data on record, last reported at $476.7 million in Q3 2023.

  • For Q3 2023, Current Assets fell 18.1% year-over-year to $476.7 million; the TTM value through Sep 2023 reached $476.7 million, down 18.1%, while the annual FY2022 figure was $474.5 million, 59.99% up from the prior year.
  • Current Assets reached $476.7 million in Q3 2023 per CGEM's latest filing, down from $498.2 million in the prior quarter.
  • Across five years, Current Assets topped out at $622.8 million in Q2 2022 and bottomed at $212.3 million in Q4 2020.
  • Average Current Assets over 4 years is $417.1 million, with a median of $423.2 million recorded in 2021.
  • The widest YoY moves for Current Assets: up 80.81% in 2022, down 27.94% in 2022.
  • A 4-year view of Current Assets shows it stood at $212.3 million in 2020, then soared by 39.71% to $296.6 million in 2021, then skyrocketed by 59.99% to $474.5 million in 2022, then grew by 0.47% to $476.7 million in 2023.
  • Per Business Quant database, its latest 3 readings for Current Assets were $476.7 million in Q3 2023, $498.2 million in Q2 2023, and $399.0 million in Q1 2023.